Investors' Chronicle cover image

How to pass on wealth, AstraZeneca & Ceres: The Companies and Markets Show

Investors' Chronicle

00:00

Enhertu priority review and AstraZeneca outlook

Julian details the FDA priority review for Enhertu and why it could become a blockbuster first-line breast cancer therapy.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app